Site Editor

Sandy Srinivas, MD


Rahul Aggarwal, MD, on Clinical Implications of the PRESTO Study Findings in Prostate Cancer

Posted: Friday, March 31, 2023

Rahul Aggarwal, MD, of the University of California, San Francisco, discusses practical clinical considerations of recent phase III findings, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with biochemically recurrent prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.